Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC)
Authors
Bernard-Tessier, A.Utriainen, T.
Cook, Natalie
Barthelemy, P.
Lallous, N.
Gleave, M.
Ikonen, T.
Riikonen, R.
Pohjanjousi, P.
Garratt, C.
Fizazi, K.
Affiliation
Institut Gustave Roussy, Villejuif, France;Issue Date
2022
Metadata
Show full item recordCitation
Bernard-Tessier A, Utriainen T, Cook N, Barthelemy P, Lallous N, Gleave M, et al. Impact of activating androgen receptor (AR) mutations on AR sensitivity to alternative ligands and response to ODM-208, a selective, first-in-class CYP11A1 inhibitor, in patients with advanced metastatic castration-resistant prostate cancer (mCRPC). Journal of Clinical Oncology. 2022 Jun;40(16). PubMed PMID: WOS:000863680301476.Journal
Journal of Clinical OncologyDOI
10.1200/JCO.2022.40.16_suppl.5057Additional Links
https://dx.doi.org/10.1200/JCO.2022.40.16_suppl.5057Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1200/JCO.2022.40.16_suppl.5057